分化型甲状腺癌患者腺叶切除术后残留甲状腺叶的放射性碘消融:系统评价与Meta分析
该系统评价与Meta分析纳入评估腺叶切除术后分化型甲状腺癌患者接受131I治疗的研究,汇总消融成功率为69%,单次给予约3.7 GBq时效果更好;结构不完全反应仅见于2%患者,生化不完全反应为8%-24%,低活度组(约1.1 GBq)较高(24%),高活度组(约3.7 GBq)较低(8%-18%);颈部疼痛(甲状腺炎所致)发生率最高达18%,多数经口服对乙酰氨基酚或短期泼尼松后缓解。
要点
- 汇总消融成功率为69%,单次给予约3.7 GBq时效果更好。
- 结构不完全反应仅见于695例中的14例(2%)。
- 生化不完全反应为8%-24%,低活度组(约1.1 GBq)为24%,高活度组(约3.7 GBq)为8%-18%。
核心结论
- 131I腺叶消融是有效的,尤其是在使用高活度131I时。
- 然而,初始治疗后的生化不完全反应率似乎略高于经典的分化型甲状腺癌初始治疗方案。
- 对于因特定个体危险因素或患者偏好而需要在腺叶切除术后完成治疗的低危至中危分化型甲状腺癌患者,应考虑放射性同位素腺叶消融。
研究设计与样本
- 本研究为系统评价与Meta分析,检索PubMed、Cochrane对照试验中心注册库、Scopus和Web of Science,检索更新至2020年1月,无语言限制。
- 纳入评估腺叶切除术后有分化型甲状腺癌证据的患者使用131I治疗的研究。
- 采用随机效应模型进行比例Meta分析(含95%置信区间),并尝试对131I成功进行Meta回归。
主要发现
- 汇总消融成功率为69%,单次给予约3.7 GBq的患者结果更好。
- 异质性高(I²检验,85%),未发现发表偏倚(Egger检验,P=0.57)。
- 结构不完全反应仅见于纳入分析的695例患者中的14例(2%)。
- 生化不完全反应见于8%-24%的患者,接受低放射性碘活度(约1.1 GBq)的患者较高(24%),接受较高放射性碘活度(约3.7 GBq)的患者较低(8%-18%)。
- 甲状腺炎所致颈部疼痛报告率最高达18%,但多数病例经口服对乙酰氨基酚或短期泼尼松后症状缓解。
关键数值与推荐
- 汇总消融成功率为69%,单次给予约3.7 GBq时结果更好。
- 结构不完全反应为695例中14例(2%)。
- 生化不完全反应为8%-24%,低活度组(约1.1 GBq)为24%,高活度组(约3.7 GBq)为8%-18%。
- 异质性I²=85%,发表偏倚Egger检验P=0.57。
临床怎么用
- 对于因特定个体危险因素或患者偏好而需要在腺叶切除术后完成治疗的低危至中危分化型甲状腺癌患者,应考虑放射性同位素腺叶消融。
局限性
- 高异质性(I²检验,85%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to conduct a systematic review and metaanalysis of studies reporting the performance of radioactive iodine (131I) therapy in differentiated thyroid cancer (DTC) patients requiring a completion treatment after lobectomy. We also evaluated the response to 131I therapy according to 2015 American Thyroid Association guidelines and the adverse events. Methods: A specific search strategy was designed to find articles evaluating the use of 131I in patients with evidence of DTC after lobectomy. PubMed, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science were searched. The search was updated until January 2020, without language restriction. Data were cross-checked and any discrepancy discussed. A proportion metaanalysis (with 95% confidence interval) was performed using the random-effects model. Metaregressions on 131I success were attempted. Results: The pooled success ablation rate was 69%, with better results in patients receiving a single administration of about 3.7 GBq; high heterogeneity was found (I2 test, 85%), and publication bias was absent (Egger test, P = 0.57). Incomplete structural responses were recorded in only 14 of 695 (2%) patients enrolled in our analysis. Incomplete biochemical responses were observed in 8%-24% of patients, with higher rates (24%) in patients receiving low radioiodine activities (∼1.1 GBq) and lower rates (8%-18%) in patients receiving higher activities of radioiodine (∼3.7 GBq). Neck pain due to thyroiditis was reported in up to 18% of patients, but in most cases, symptoms resolved after oral paracetamol or a short course of prednisone. Conclusion: Lobar ablation with 131I is effective, especially when high 131I activities are used. However, the rate of incomplete biochemical response to initial treatment appears to be slightly higher than in the classic scheme of initial treatment of DTC. Radioisotopic lobectomy should be considered for patients with low- to intermediate-risk DTC requiring completion treatment after lobectomy due to specific individual risk factors or patient preferences.
引用
- Piccardo A, Trimboli P, Bottoni G, et al. Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis. J Nucl Med. 2020. PMID: 32332146. doi:10.2967/jnumed.120.244384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。